EuroBiotech—More articles of note

Newspapers

> ASIT Biotech outlined plans to raise cash for its phase 3 grass pollen induced rhinoconjunctivitis trial. The Belgian biotech plans to issue 3 million new shares. Statement

> Horama raised €19 million ($22 million). The round gives the Christine Placet-helmed gene therapy specialist the means to move its retinitis pigmentosa candidate into the clinic. Release (PDF)

> Redx escaped from administration. The British biotech is now working to get its lead cancer drug into the clinic next year. Statement (PDF) 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Verona Pharma pulled forward the anticipated readout of top-line data from its phase 2b COPD trial. Management now expects to have date by the middle of next year, as opposed to the second half, because enrollment is proceeding faster than forecast. Release

> Erytech provided more details about its Nasdaq IPO. The French biotech is looking to raise about $125 million by offloading shares for $23 to $24 a piece. Release

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.